July 8, 2025 10:00 AM EDTUpdated 11:07 AM
People
Pharma

Bio­phar­ma's 20 high­est-paid CEOs of 2024 with $20M+ pay­days

Andrew Dunn

Senior Biopharma Correspondent

The typ­i­cal CEO of a pub­lic bio­phar­ma com­pa­ny made $4.73 mil­lion in 2024, a 40% jump from last year’s me­di­an fig­ure.

But a hand­ful of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Shell com­pa­ny Con­cen­tra has found its rhythm, with Car­go Ther­a­peu­tics as its lat­est buy­out tar­get

Ex­clu­sive: Start­up rais­es $45M for uni­ver­sal flu vac­cines made with mR­NA

ProKid­ney's stock shoots high­er af­ter mixed Phase 2 da­ta

FDA chief calls for 'mean­ing­ful' re­duc­tion of an­i­mal test­ing for new drugs

Re­cur­sion takes full rights to rare ge­net­ic dis­or­der drug; CStone out-li­cens­es can­cer drug in Eu­rope

sponsored

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

A service from the Financial Times